<DOC>
	<DOCNO>NCT00060866</DOCNO>
	<brief_summary>This study examine effectiveness drug propranolol prevent faint patient sympathoadrenal imbalance ( SAI ) . SAI particular pattern nervous system chemical response blood vessel skeletal muscle remain constricted appropriately stand long time . This low blood pressure cause fainting . Propranolol Inderal ( register trademark ) Food Drug Administration-approved drug belongs class drug call beta-blockers . These drug slow heart rate maintain blood pressure certain situation . Patients 18 year age old SAI may eligible study . Screening include tilt table test , describe , determine patient particular chemical pattern blood . Patients enrol study take propranolol pill increase dos first week study determine proper dose individual . Then , drug stop experimental phase study begin . In phase , patient randomly assign take either propranolol placebo ( look-alike pill active ingredient ) 4 day . On fourth day , patient undergoes tilt table test determine whether treatment affect patient 's ability tolerate tilt . For test , patient lie pad table motorized tilt mechanism move patient flat position upright position 10 second . The patient remain upright 45 minute follow measurement take : - Arterial blood pressure monitor arterial blood sampling . A catheter ( thin , plastic tube ) insert artery elbow crease area arm wrist . This catheter allow continuous blood pressure monitor sample arterial ( oxygenate ) blood tilt test . - Venous blood sample measurement epinephrine norepinephrine release . A catheter insert vein arm , one collect venous ( deoxygenate ) blood sample , inject radioactive epinephrine ( adrenaline ) norepinephrine ( noradrenaline ) . These radioactive drug , , tracer , allow measurement rate release body 's norepinephrine epinephrine bloodstream . - Physiologic measurement . Blood pressure , heart rate , EKG measure continuously tilt test session , blood flow skin electrical conduction measure intermittently . Blood flow measure use sensor apply skin blood pressure cuff around limb . For skin blood flow measurement , laser beam scan skin surface . The skin electrical conduction test measure well skin conduct electricity . This measured sensor place finger site . The effect test drug allow wear 1 week , entire tilt test procedure repeat . Patients give propranolol first test session take placebo repeat session , give placebo take propranolol .</brief_summary>
	<brief_title>Propranolol Treat Fainting Due Sympathoadrenal Imbalance</brief_title>
	<detailed_description>This protocol evaluate treatment oral propranolol particular form neurocardiogenic syncope ( NCS ) , characterize neuroendocrine pattern call , sympathoadrenal imbalance , ( SAI ) . In SAI , plasma epinephrine level increase progressively great extent plasma norepinephrine level , development NCS . The SAI pattern associate skeletal muscle vasodilation , also precede NCS . We hypothesize increased occupation beta-2 adrenoceptors skeletal muscle high circulate epinephrine level precipitate neurocirculatory positive feedback loop lead NCS . In protocol test hypothesis use non-selective beta-adrenoceptor blocker , propranolol . We predict patient previously document SAI tilt-evoked NCS , propranolol treatment improve orthostatic tolerance follow-up tilt table testing , randomize , crossover-design , placebo-controlled , double-blind trial . The main department measure occurrence tilt-induced NCS , duration tilt tolerance , hemodynamic neurochemical index SAL , patient questionnaire report .</detailed_description>
	<mesh_term>Syncope</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>INCLUSION CRITERIA : Subjects patient referred evaluation chronic orthostatic intolerance . Patients enter therapeutic trial determine NCS SAI screen evaluation . Participation protocol offer individual 18 year old old , independently gender , race , advanced age , ethnicity , religion , demographic sociopolitical classification . EXCLUSION CRITERIA : Age : Minors younger 18 year old exclude . Advanced age constitute exclusion criterion . Risk : A candidate subject exclude , judgement Principal Investigator Clinical Director , protocol participation would place subject subject substantially increase acute medical risk . This include risk associate air travel NIH . A candidate subject exclude , opinion Principal Investigator Clinical Director , medical risk outweigh potential scientific benefit . Disqualifying Conditions : A candidate subject exclude disqualify condition . Examples disqualify condition history asthma chronic obstructive pulmonary disease require bronchodilator , hepatic renal failure , atrioventricular block degree , bradycardia , symptomatic congestive heart failure , severe anemia , psychosis , refractory ventricular arrhythmia , symptomatic coronary heart disease , insulindependent diabetes mellitus , WolffParkinsonWhite syndrome , peripheral vascular disease . Patients know suspected allergy hypersensitivity propranolol exclude study . A positive HIV test result necessarily exclude patient participate . Medications : A candidate subject exclude clinical consideration require patient continue treatment drug likely interfere scientific result . Patients must take medication daily follow category exclude : anticoagulant , tricyclic , antidepressant , barbiturate , aspirin , acetaminophen , insulin , bronchodilator . Patients unable discontinue nicotine , caffeine , alcohol temporarily exclude . Patients chronic alcohol intake exclude . Patients discontinue medication patient patient 's doctor discuss Principal Investigator , Associate Investigator , Research Nurse . If decided discontinuing medication would unsafe , patient exclude study . Herbal Medicines Dietary Supplements : Certain herbal medicine dietary supplement know suspect interfere experimental result , herbal medicine dietary supplement must discontinue enrollment study . For many herbal medicine dietary supplement , mechanism action therefore possible effect experimental result unknown . In case subject wish continue herbal medicine dietary supplement study , search available medical literature fail identify effect know expect interfere experimental result , subject may participate . Practical Limitations : Patients feel would difficult technically carry test procedure exclude . Pregnancy : Pregnant lactate woman exclude . A blood test pregnancy conduct woman childbearing potential , intake evaluation also drug treatment phase . During course protocol , subject woman childbearing potential advise practice adequate contraception . Termination Participation : Subjects may refuse certain test procedure , may terminate participation early , without loss benefit previously entitle . The Investigators may also exclude subject participation , event know suspect falsification medical history information refusal undergo plan test procedure , without loss benefit subject previously entitle .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>Beta-Adrenoceptors</keyword>
	<keyword>Beta-Adrenoceptor Blocker</keyword>
	<keyword>Neurocardiogenic Syncope</keyword>
	<keyword>Chronic Orthostatic Intolerance</keyword>
	<keyword>Neurocardiogenic</keyword>
	<keyword>Dysautonomia</keyword>
	<keyword>Autonomic Nervous System</keyword>
	<keyword>Nurocardiogenic Syncope</keyword>
	<keyword>NCS</keyword>
	<keyword>Sympathoadrenal Imbalance</keyword>
	<keyword>SAI</keyword>
	<keyword>Orthostatic Intolerance</keyword>
</DOC>